MFOLFIRINOX or Gemcitabine / Nab-paclitaxel Followed by Pancreatectomy for Patients with Borderline Resectable Pancreatic Adenocarcinoma. a Pilot Feasibility Study.
This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.
• 1\. Men and women 18 years of age or older who present with biopsy proven borderline resectable pancreatic adenocarcinoma who are medically fit for surgery as per assessment by treating surgeon.
• 2\. Age ≤ 79 years 3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 4. Normal bone marrow and organ function
⁃ Absolute neutrophil count (ANC) = or \> 1500, platelets \> 100K
⁃ Total bilirubin \<1.5x upper limit of normal (ULN)
⁃ Alanine transaminase (ALT), Aspartate aminotransferase (AST) \< 3 x ULN
⁃ Creatinine \<150umol/L
⁃ Normal prothrombin time and international normalized ratio (INR) 5. Able to provide written informed consent